| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Lakefront Biotherapeutics$29.47
-0.33 (-1.11%)
D 20Pipeline Score Richly Valued Biotech · Clinical
Market Cap
1.82 B
EPS
8.67
P/E Ratio
3.18 $
Value Trade
11.06 M
0 %
Week
-5.44 %
1 Month
-18.57 %
3 Month
-8.94 %
6 Month
-62.89 %
5 Year
250.19 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
165.29 K
52 Week Range
26.42 - 37.78
% held by Insiders
25.35 %
% held by Institutions
24.06 %
Enterprise Value
-1.61 B
Total Shares
65.90 M
Short %
4.55 %
Float Shares
49.19 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lakefront Biotherapeutics
284Total events
1Upcoming
93Tier-1 (high impact)
2015 – 2027Coverage
Upcoming catalysts 1
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
◆Management ChangeCorporate
Subscribe to view catalyst details
TBD
◆ATM ProgramCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D20
Pipeline Score $9M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCapLakefront Biotherapeutics faces pipeline headwinds (20/100), with $26M risk-adjusted pipeline value, led by OM336 in Sjogrens Disease (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OM336 Small molecule | AIHA - Warm Autoimmune Hemolytic Anemia | Phase 1 | NCT07083960 | 7% | $26M | RECRUITING | 32 | - | - | Sep 1, 2027 | - | Jul 14, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
filgotinib | rheumatoid arthritis | Phase 2b | 2015-09-28 | 877 patients; 24-week Phase 2B studies; three-fold more JAK1 selective than ABT-494; more than 700 patient-years of treatment experience; more than 500 years at the highest 200 mg dose Read More | Regulated information 25 September 2015, 16.45 CET Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritis Galapagos regains all unencumbered rights to filgotinib Filgotinib is the most selective JAK1 inhibito Read More | |
filgotinib | rheumatoid arthritis | Phase 2b | 2015-09-28 | 877 patients; 24-week Phase 2B studies; three-fold more JAK1 selective than ABT-494; more than 700 patient-years of treatment experience; more than 500 years at the highest 200 mg dose Read More | Regulated information 25 September 2015, 16.45 CET Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritis Galapagos regains all unencumbered rights to filgotinib Filgotinib is the most selective JAK1 inhibito Read More | |
filgotinib | rheumatoid arthritis | Phase 2b | 2015-09-28 | 877 patients; 24-week Phase 2B studies; three-fold more JAK1 selective than ABT-494; more than 700 patient-years of treatment experience; more than 500 years at the highest 200 mg dose Read More | Regulated information 25 September 2015, 16.45 CET Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritis Galapagos regains all unencumbered rights to filgotinib Filgotinib is the most selective JAK1 inhibito Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LKFT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LKFT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LKFT▼ -1.1%today
Lakefront kondigt het terugtreden van Paulo Fontoura uit de Raad van Bestuur aan na zijn benoeming tot Global Head of Research & Development bij Sanofi
Lakefront Biotherapeutics announced that Dr. Paulo Fontoura has resigned from its Board of Directors following his appointment as Global Head of Research & Development at Sanofi. The company praised Fontoura for his insights during his tenure and expressed intentions to appoint a successor soon. This leadership change reflects Fontoura's career advancement in the biopharma industry.
Read more →LKFT▼ -1.1%today
Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi
Lakefront Biotherapeutics announced the resignation of Dr. Paulo Fontoura from its Board of Directors following his appointment as Global Head of R&D at Sanofi. The Chair of the Board, Gino Santini, congratulated Fontoura and thanked him for his contributions. Lakefront plans to appoint a successor soon.
Read more →LKFTLakefront ontvangt transparantieverklaring van Madison Avenue Partners
Lakefront Biotherapeutics NV has received a transparency declaration from Madison Avenue Partners, indicating that the latter has exceeded the 5% threshold of voting rights as of June 15, 2026. This declaration highlights Madison Avenue Partners' growing stake in Lakefront, which now holds 5.31% of the company's shares. Lakefront is focused on developing treatments for serious conditions with unmet medical needs.
Read more →LKFTLakefront Receives Transparency Notification from Madison Avenue Partners
Lakefront Biotherapeutics NV received a transparency notification from Madison Avenue Partners, indicating that they crossed the 5% threshold of voting rights on June 15, 2026. This acquisition reflects Madison Avenue's growing interest in Lakefront, as they now hold 5.31% of the company's voting rights. The notification is part of compliance with Belgian transparency legislation.
Read more →LKFTLakefront Announces Initiation of €50 Million Stock Repurchase Program
Lakefront Biotherapeutics has launched a €50 million stock repurchase program, allowing the company to buy back shares until December 31, 2026. This initiative aims to enhance shareholder value and follows a previous agreement with Gilead. The program will be executed in compliance with industry standards and will provide regular updates during its duration.
Read more →LKFTLakefront kondigt start aan van aandeleninkoopprogramma ter waarde van € 50 miljoen
Lakefront Biotherapeutics has announced the initiation of a €50 million share buyback program, which is part of a broader strategy following a transaction with Gilead. The program allows for stock purchases until December 31, 2026, aiming to enhance shareholder value. Regular updates will be provided in compliance with regulations.
Read more →LKFTLakefront Appoints Eric Hedrick, MD, as Chief Medical Officer
Lakefront Biotherapeutics has appointed Eric Hedrick, MD, as Chief Medical Officer, enhancing its leadership team following the acquisition of Ouro Medicines. Dr. Hedrick, who has over 25 years of experience in the biotech industry, will guide the development of the company's R&D pipeline. His appointment is seen as a crucial step in Lakefront's strategic transformation.
Read more →LKFTLakefront benoemt dr. Eric Hedrick tot Chief Medical Officer
Lakefront Biotherapeutics has appointed Dr. Eric Hedrick as Chief Medical Officer. This role is pivotal for the company's strategic transformation following the acquisition of Ouro Medicines. Dr. Hedrick, with 25 years of experience in drug development, will lead the development of new clinical programs, enhancing Lakefront's R&D pipeline.
Read more →LKFTLakefront Receives Transparency Notification from Bank of America
Lakefront Biotherapeutics NV received a transparency notification from Bank of America, indicating that the bank crossed the 5% threshold of voting rights. As of May 20, 2026, Bank of America holds 9.30% of Lakefront's shares, following an acquisition on May 13, 2026. This significant stake may influence Lakefront's strategic direction.
Read more →LKFTLakefront ontvangt transparantieverklaring van Bank of America
Lakefront Biotherapeutics NV has received a transparency declaration from Bank of America, indicating that the bank has surpassed the 5% threshold of voting rights in the company. As of May 20, 2026, Bank of America holds 9.30% of Lakefront's outstanding shares, reflecting its growing investment interest. This development may enhance Lakefront's financial stability and growth prospects.
Read more →LKFTGalapagos Reports First Quarter 2026 Financial Results and Provides Business Update
Galapagos, soon to be renamed Lakefront Biotherapeutics, reported its Q1 2026 financial results, highlighting a collaboration with Gilead for a T cell engager therapy. The company anticipates a strong cash position despite expected expenditures related to the acquisition of Ouro Medicines. Management expressed optimism about the strategic direction and financial flexibility moving forward.
Read more →LKFTGalapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026 Mechelen, Belgium
Galapagos NV announced that shareholders at the Annual and Extraordinary Shareholders' Meetings held on April 28, 2026, approved all proposed resolutions. The company's CEO, Henry Gosebruch, thanked shareholders for their support and highlighted the commitment to a transformative strategy. Gino was welcomed as the new Chair of the Board, emphasizing the importance of his expertise in guiding the company. Galapagos continues to focus on bringing meaningful medicines to patients in need.
Read more →LKFTGalapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases New collaboration structure achieves meaningfully improved financial terms and f
Galapagos has entered into a binding agreement with Gilead to advance a T cell engager program for autoimmune diseases, bringing improved financial terms for Galapagos. This collaboration focuses on gamgertamig, which has shown promising efficacy and safety in clinical trials for severe autoimmune conditions. With an upfront cash consideration of $1.675 billion and potential milestone payments, the partnership aims to leverage Gilead's experience in drug development, while Galapagos retains a significant cash reserve for further strategic opportunities. The agreement is set to strengthen both companies in the competitive biotech landscape.
Read more →LKFTGalapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders' Meetings Mechelen, Belgium
Galapagos NV published its 2025 annual report and announced upcoming Annual and Extraordinary Shareholders' Meetings scheduled for April 28, 2026. Key agenda items for the AGM include board appointments and re-appointment of the statutory auditor. The EGM will discuss significant proposals such as a name change to Lakefront Biotherapeutics and share repurchase plans. The company emphasizes its commitment to bringing innovative medications to patients with unmet medical needs, despite some uncertainties associated with the proposals.
Read more →LKFTGalapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update Appointments of new CEO, CFO, and seasoned business development leaders with proven track records of executing strategic tran
Galapagos NV reported its half-year 2025 financial results, indicating a strong cash position of 3.1 billion but also significant operational losses of 215.7 million. The company has appointed a new CEO and CFO alongside seasoned business development leaders to steer its strategic direction, including potential divestitures of certain segments. The cell therapy pipeline continues to show positive clinical developments, despite the ongoing evaluation of strategic alternatives for its business units. The management remains optimistic about future growth and cash management strategies.
Read more →LKFTGalapagos Publishes 2024 Annual Report and Announces Annual Shareholders Meeting Mechelen, Belgium
Galapagos NV has released its annual report for the financial year 2024 and is set to hold its Annual Shareholders Meeting on April 29, 2025. Key agenda items include the appointment of Mr. Oleg Nodelman as a Non-Executive Non-Independent Director. Notably, the plan to separate Galapagos into two publicly traded entities will not be discussed at this meeting, with an Extraordinary Shareholders Meeting expected mid-2025 to address this issue. Shareholders must comply with specific requirements to participate in the AGM.
Read more →LKFTCERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH [***] . SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETI
A Separation Agreement has been entered into by Gilead Sciences Inc. regarding the restructuring and potential acquisitions of the company. The document outlines definitions, provisions for spin-offs, capital allocations, and various responsibilities of involved parties. Specific financial arrangements and the treatment of confidential information have also been included, reflecting the complexity of the corporate restructuring process. As per the article, certain critical details have been redacted to protect competitive interests.
Read more →LKFTGalapagos reports half-year 2024 financial results and provides second quarter
Galapagos NV reported its half-year 2024 financial results, showcasing a promising trajectory in regulatory filings and pipeline initiatives. The company has submitted key Investigational New Drug (IND) applications for its CAR-T cell therapies and plans to enhance its collaborations in cell therapy to broaden its treatment portfolio. Financially, total net revenues increased by 18% compared to the previous year, although operating losses have also escalated significantly. The firm reaffirmed its cash burn guidance for 2024, indicating ongoing financial challenges.
Read more →LKFTGalapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders Meetings Publication of annual report for financial year 2023 Annual Shareholders Meeting resolutions include approval of revised
Galapagos NV has published its annual report for the financial year 2023 and announced the dates for its Annual and Extraordinary Shareholders Meetings, scheduled for April 30, 2024. The meetings will cover various agenda items including the approval of a revised Remuneration Policy and the reappointment of Dr. Elisabeth Svanberg as a Non-Executive Independent Director. Additionally, new appointments are proposed for the board, indicating ongoing governance and strategic development. The annual report is available online for stakeholders to review.
Read more →LKFTGalapagos announces first half-year 2023 financial results Half-year 2023 key financials Group revenues of 328.8 million Jyseleca net sales of 54.3 million Cash and current financial investments of 3.9 billion on 30 June
Galapagos announced its first half-year 2023 financial results, reporting total net revenues of 328.8 million, representing a 20% increase from the previous year. A notable increase in collaboration revenues was attributed to the Gilead partnership, which contributed 154.9 million. However, the company revised its net sales guidance for Jyseleca downwards due to a changed competitive landscape. Despite these challenges, Galapagos reported a net profit of 28.3 million and maintains a robust cash position of 3.9 billion.
Read more →LKFTGalapagos publishes 2022 annual report and announces Annual Shareholders Meeting Publication of annual report for financial year 2022 Annual Shareholders Meeting proposed resolutions include re-appointment of Board membe
Galapagos NV has published its annual report for the financial year 2022 and announced the date for its Annual Shareholders Meeting, scheduled for April 25, 2023. The report details the company's performance and financial figures. Key agenda items for the meeting include the re-appointment of board members Peter Guenter, Daniel O'Day, and Linda Higgins, as well as the appointment of a new statutory auditor. Shareholders are required to fulfill certain formalities to attend the meeting.
Read more →LKFTJ.P. Morgan Healthcare Conference
During the J.P. Morgan Healthcare Conference, LKFT shared insights into its strategic priorities, particularly regarding collaborations and development plans related to CAR-T therapies. The company highlighted ongoing clinical studies, including the ATALANTA-1 study, which is crucial for assessing its CD19 CAR-T products. However, potential risks were communicated, such as regulatory delays and uncertainties that may impact drug approvals and market performance. Overall, the presentation reflects a mix of optimism about future developments amid caution regarding inherent risks in biopharma.
Read more →LKFTGalapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results Clear path forward for accelerated growth and value creation Reshape innovation model and build fit-for-purpose organiza
Galapagos announces strategy to accelerate innovation and reports strong third quarter R&D and Strategy Webcast presentation at R&D Update tomorrow in New York, 4 November 2022, 13.00 15.30 CET / 8 am 10.30 am EDT, www.glpg.com Mechelen, Belgium; 3 November 2022, 21.01 CET; r
Read more →LKFTFirst key steps in pipeline rebuild and strong commercial progress in H1 2022 First half-year 2022 financial results: Jyseleca net sales reached 35.4 million Group revenues of 274.0 million Operating loss of 97.5 million
First key steps in pipeline rebuild and strong commercial progress in H1 2022 presentation tomorrow, 5 August 2022, at 14.00 CET / 8 AM ET, www.glpg.com, Mechelen, Belgium; 4 August 2022, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) today announced i
Read more →LKFTGalapagos demonstrates regulatory and commercial progress in Q1 2022 First three months 2022 financial results: Jyseleca ne t sales reached 14.4 million Group revenues +20% to 136.3 million Operating loss -58% to 21.1 mi
Galapagos demonstrates regulatory and commercial Webcast presentation tomorrow, 6 May 2022, at 14.00 CET / 8 AM ET, www.glpg.com, + 32 (0)2 793 38 47, code 9523309 Mechelen, Belgium; 5 May 2022, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) today ann
Read more →LKFTGalapagos publishes 2021 annual report and announces extraordinary and annual shareholders meetings Proposal of one-tier board structure & appointment of three new directors Mechelen, Belgium; 24 March 2022, 21.01 CET; r
Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders meetings Proposal of one-tier board structure & appointment of three new directors Mechelen, Belgium; 24 March 2022, 21.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLP
Read more →LKFTGalapagos reports commercial and operational progress at Q3 financial results First nine months 2021 financial results: Group revenues of 317.9 million Operating loss of 175.7 million Net loss of 119.6 million Cash and c
Galapagos reports commercial and operational progress at Q3 financial results Webcast presentation tomorrow, 5 November 2021, at 13.00 CET / 8 AM ET, www.glpg.com, +32 2 793 38 47, code 4987105 Mechelen, Belgium; 4 November 2021, 22.01 CET; regulated information Galapagos NV
Read more →LKFTGalapagos reports H1 financial results with refocused pipeline and operational progress First half-year 2021 financial results: o Group revenues and other income of 277.2 million o Operating loss of 97.6 million o Net lo
Galapagos reports H1 financial results with refocused pipeline and operational progress Webcast presentation tomorrow, August 6, 2021, at 14.00 CET / 8 AM ET, www.glpg.com, +32 2 793 38 47, code 8245817 Mechelen, Belgium; August 5, 2021, 22.01 CET; regulated information - Galap
Read more →LKFTGalapagos refocuses pipeline and rightsizes operations First three months 2021 financial results: Group revenues and other income of 124.2 million Operating loss of 50.8 million Net profit of 9.4 million Cash and current
Galapagos refocuses pipeline and rightsizes operations Webcast presentation tomorrow, 07 May 2021, at 14.00 CET / 8 AM ET, www.glpg.com, +32 2 793 38 47, code 5042688 Mechelen, Belgium; 06 May 2021, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) announ
Read more →LKFTPublication of the annual report and invitation to the ordinary shareholders meeting Mechelen, Belgium; 25 March 2021; 21.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report f
Publication of the annual report and invitation to the ordinary shareholders meeting Mechelen, Belgium; 25 March 2021; 21.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for the financial year 2020. The annual report for the fi
Read more →LKFTGalapagos reports Q3 2020 results First nine months 2020 financial results: Group revenues and other income of 368.6 million Operating loss of 163.2 million Net loss of 247.6 million Cash and current financial investment
Galapagos reports Q3 2020 results Webcast presentation tomorrow, 06 November 2020, at 14.00 CET / 8 AM ET, www.glpg.com, +32 2 793 38 47, code 8542327 Mechelen, Belgium; 5 November 2020, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) announces its unau
Read more →LKFTGalapagos reports solid H1 2020 progress First half-year 2020 financial results: o Group revenues and other income of 224.6 million o Operating loss of 130.8 million o Net loss of 165.6 million o Cash and current financi
Galapagos reports solid H1 2020 progress Webcast presentation tomorrow, 7 August 2020, at 14.00 CET / 8 AM ET, www.glpg.com, +32 2 404 0659, code 8997710 Mechelen, Belgium; 6 August 2020, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces its un
Read more →LKFTOn track for clinical read-outs and commercial readiness in 2020 First three-month 2020 financial results: Group revenues and other income of 106.9 million Operating loss of 44.6 million Net loss of 50.6 million Cash and
On track for clinical read-outs and commercial readiness in 2020 Webcast presentation tomorrow, 8 May 2020, at 14.00 CET / 8 AM ET, www.glpg.com, +32 2 404 0659, code 6118715 Mechelen, Belgium; 7 May 2020, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG)
Read more →LKFTPublication of the annual report and invitation to the ordinary and extraordinary shareholders meetings Mechelen, Belgium; 27 March 2020, 21.15 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) published
Publication of the annual report and invitation to the ordinary and extraordinary shareholders meetings Mechelen, Belgium; 27 March 2020, 21.15 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for the financial year 2019. The annua
Read more →LKFTSolid third quarter 2019 performance with strong balance sheet for continued R&D growth First nine month financial results: Group revenues of 752.5 million Operating profit of 393.0 million Net profit of 265.3 million Ca
Solid third quarter 2019 performance with strong balance sheet for continued R&D growth Webcast presentation tomorrow, 25 October 2019, at 14.00 CET/8 AM ET, www.glpg.com, +32 2 404 0659, code 6653712 Mechelen, Belgium; 24 October 2019, 22.01 CET; regulated information Galapago
Read more →LKFTInvitation to the special and extraordinary shareholders meetings Mechelen, Belgium; 20 September 2019, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) invites its shareholders to a special and ex
special and extraordinary shareholders meetings Mechelen, Belgium; 20 September 2019, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) invites its shareholders to a special and extraordinary shareholders meeting. On 14 July 2019, Galapagos NV (the Compan
Read more →LKFTGILEAD AND GALAPAGOS COMPLETE CLOSING OF THEIR TRANSFORMATIVE RESEARCH AND DEVELOPMENT COLLABORATION Foster City, Calif. and Mechelen, Belgium; 23 August 2019; 22.01 CET; regulated information Gilead Sciences, Inc. (NASD
GILEAD AND GALAPAGOS COMPLETE CLOSING OF THEIR TRANSFORMATIVE RESEARCH AND DEVELOPMENT COLLABORATION Foster City, Calif. and Mechelen, Belgium; 23 August 2019; 22.01 CET; regulated information Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today
Read more →LKFTStrong clinical progress in H1, and transformative collaboration with Gilead announced · First half-year financial results: o Group revenues of €108.5 million o Operating loss of €97.6 million o Net lo
Strong clinical progress in H1, and transformative collaboration with Gilead announced Webcast presentation tomorrow, 26 July 2019, at 14.00 CET/8 AM ET, www.glpg.com, +32 2 404 0659, code 6080337 Mechelen, Belgium; 25 July 2019, 22.01 CET; regulated information Galapagos NV (E
Read more →LKFTGalapagos reports on historic first quarter 2019 Key Q1 2019 results: Group revenues of 40.9 million Operating loss 53.2 million Net loss of 48.7 million End of first quarter cash and cash equivalents 1.2 billion Competi
Galapagos reports on historic first quarter 2019 Key Q1 2019 results: Webcast presentation tomorrow, 26 April 2019, at 14.00 CET/8 AM ET, +32 2 404 0659, code 1452466, www.glpg.com Mechelen, Belgium; 25 April 2019, 22.01 CET; regulated information Galapagos NV (Euronext & NAS
Read more →LKFTPublication of the annual report and invitation to the annual shareholders meeting Nomination of Mr. Peter Guenter for Galapagos board of directors Mechelen, Belgium; 29 March 2019, 22.15 CET; regulated information Galap
Publication of the annual report and invitation to the annual shareholders meeting Nomination of Mr. Peter Guenter for Galapagos board of directors Mechelen, Belgium; 29 March 2019, 22.15 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) published its annual re
Read more →LKFTHallmark third quarter 2018 and Annual R&D Update at Galapagos First nine months financial results: Group revenues increased by 98.7 million to 205.1 million Operating loss decreased by 9.1 million to 53.5 million Net lo
Hallmark third quarter 2018 and Annual R&D Update at Galapagos Webcast presentation to be combined with our Annual R&D Update event tomorrow, 25 October 2018, at 16.15 CET/10:15 AM ET, www.glpg.com, +32 (0)2 404 0659, code 2357358 Mechelen, Belgium; 24 October 2018, 22.03 CET;
Read more →LKFTProductive first half-year at Galapagos · First half-year financial results: o Group revenues of €101.9 million o Operating loss of €65.8 million o Net loss of €59.1 million o Cash and cash equi
Productive first half-year at Galapagos Webcast presentation tomorrow, 3 August 2018, at 14.00 CET/8 AM ET, www.glpg.com, +32 2 404 0659, code 1122269 Mechelen, Belgium; 2 August 2018, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) announces its unaudit
Read more →LKFTGalapagos reports first quarter 2018 results Key Q1 2018 results: Group revenues of 44.8 million Operating loss 32.0 million Net loss of 37.3 million End of first quarter cash and cash equivalents 1.1 billion Clinical pr
Galapagos reports first quarter 2018 results Key Q1 2018 results: Webcast presentation tomorrow, 26 April 2018, at 14.00 CET/8 AM ET, +32 2 404 0659, code 5747918 www.glpg.com Mechelen, Belgium; 25 April 2018, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ:
Read more →LKFTPublication of the annual report and invitation to the annual shareholders meeting Mechelen, Belgium; 23 March 2018, 21.30 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for
Publication of the annual report and invitation to the annual shareholders meeting Mechelen, Belgium; 23 March 2018, 21.30 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for the financial year 2017. The annual report for the fina
Read more →LKFTGalapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline Substantial progress in R&D Inflammation: Studies with filgotinib started in uveitis and lupus membranous nephropathy IL-17C an
Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline presentation tomorrow, 27 October 2017, at 14.00 CET/8 AM ET, www.glpg.com, +32 2 404 0659, code 2890376 26 October 2017, 22.01 CET; regulated information Galapagos NV (Euronext & NASDA
Read more →LKFTSolid financials support R&D progress First half-year financial results: Revenues 73.0 M, an increase of 24.3 M compared to H1 2016 Operating loss 32.9 M, an increase of 8.6 M compared to H1 2016 Cash on 30 June 2017 of
Solid financials support R&D progress Webcast presentation tomorrow, 28 July 2017, at 14.00 CET/8 AM ET, www.glpg.com, +32 2 403 7297, code 4659682 Mechelen, Belgium; 27 July 2017, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) announces its unaudited f
Read more →LKFTGalapagos reports first quarter 2017 results Key Q1 2017 results: Group revenues more than doubled to 39.9 million (+169%) Operating loss reduced by 55% to 11.2 million Net loss of 13.6 million End of first quarter cash
Galapagos reports first quarter 2017 results Key Q1 2017 results: Webcast presentation tomorrow, 28 April 2017, at 14.00 CET/8 AM ET, +32 2 404 0659 www.glpg.com Mechelen, Belgium; 27 April 2017, 22.00 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) present
Read more →LKFTGalapagos announces launch of proposed public offering Mechelen, Belgium, 17 April 2017, 22.10 CET, regulated information Galapagos NV (Euronext & NASDAQ: GLPG) announced today that it intends to offer and sell, subject
Galapagos announces launch of proposed public offering Mechelen, Belgium, 17 April 2017, 22.10 CET, regulated information Galapagos NV (Euronext & NASDAQ: GLPG) announced today that it intends to offer and sell, subject to market and other conditions, $275 million of its ordina
Read more →LKFTMarch 2017, 22.00 CET Publication of the annual report and invitation to the annual and extraordinary shareholders meetings Mechelen, Belgium; 23 March 2017; regulated information Today Galapagos NV (Euronext & NASDAQ: G
23 March 2017, 22.00 CET Publication of the annual report and invitation to the annual and extraordinary shareholders meetings Mechelen, Belgium; 23 March 2017; regulated information Today Galapagos NV (Euronext & NASDAQ: GLPG) published its Annual Report for the financial ye
Read more →LKFTRobust progress in Q3 2016
Regulated information Robust progress in Q3 2016 Financial results of the first nine months: Group revenues increased by 17.8 M to 65.0 M Operating loss reduced by 14.8 M to 48.5 M End of third quarter cash 938.8 M Start FINCH Phase 3 program with filgotinib in rheumatoid
Read more →LKFTRegulated information 28 July 2016, 22.00 CET Focus on filgotinib and cystic fibrosis First half-year financial results: Revenues 48.8 M, an increase of 11.9 M compared to H1 2015 Operating loss 24.3 M, an improvement of
Focus on filgotinib and cystic fibrosis Webcast presentation tomorrow 29 July at 14.00 CET/8 AM ET, www.glpg.com, +32 2 404 0659, code 4067587 Mechelen, Belgium; 28 July 2016 Galapagos NV (Euronext & NASDAQ: GLPG) announces its unaudited first half-year results, which are furt
Read more →LKFTRegulated information 23 June 2016, 7.30 CET Invitation to the Special and Extraordinary Shareholders Meetings of 26 July 2016 - Nomination of Mary Kerr for Galapagos Board of Directors Mechelen, Belgium; 23 June 2016 Ga
Invitation to the Special and Extraordinary Shareholders Meetings of 26 July 2016 - Nomination of Mary Kerr for Galapagos Board of Directors Mechelen, Belgium; 23 June 2016 Galapagos NV (Euronext & NASDAQ: GLPG) has the honor to invite its Shareholders, Warrant Holders, Directo
Read more →LKFTRegulated information 19 January 2016, 22.40 CET Galapagos and Gilead complete closing of their global collaboration for filgotinib Mechelen, Belgium and Foster City, CA, USA, 19 January 2016 Galapagos NV (Euronext & NAS
Galapagos and Gilead complete closing of their global collaboration for filgotinib Mechelen, Belgium and Foster City, CA, USA, 19 January 2016 Galapagos NV (Euronext & NASDAQ: GLPG) and Gilead Sciences, Inc. (NASDAQ: GILD) announced today the closing and entry into force of th
Read more →LKFTRegulated information 25 September 2015, 16.45 CET Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritis Galapagos regains all unencumbered rights to filgotinib Filgotinib is the most selective JAK1 inhibito
Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritis Galapagos to hold a conference call open to the public today at 17.15 CET/11:15 AM EDT UK: +44 330 336 6025 USA: +1 719 325 2556 Belgium: +32 2400 6966 NL: +31 207 940454 France: +33 176 7722 61 Mechelen,
Read more →LKFTRegulated information 10 August 2015, 22.00 CET DARWIN 2 24-week monotherapy data in RA confirm previous results and support best-in-class potential for filgotinib ACR50 responses up to 45% as once-daily monotherapy DAS2
DARWIN 2 24-week monotherapy data in RA confirm previous results and support best-in-class potential for filgotinib Webcast presentation of the results to be held on 11 August 2015, 16.00 CET/10 AM EDT/ 8 AM PDT, +32 2 404 0660, access code 1973880, more call number info furthe
Read more →LKFTRegulated information 5 August 2015, 22.00 CET Galapagos on track to deliver on pipeline in second half 2015 Half-year financial results 2015 ? Filgotinib shows promising efficacy and potentially differentiated safety pr
information 5 August 2015, 22.00 CET Galapagos on track to deliver on pipeline in second half 2015 Half-year financial results 2015 ? Filgotinib shows promising efficacy and potentially differentiated safety profile in DARWIN 1 and 2 Phase 2B studies ? Phase 2 readouts expect
Read more →LKFTRegulated information 29 July 2015 Galapagos selective JAK1 inhibitor filgotinib meets key efficacy endpoints, shows ACR70 responses up to 39%, and maintains safety profile after 24 weeks of treatment in DARWIN 1 Phase 2
Galapagos selective JAK1 inhibitor filgotinib meets key efficacy endpoints, shows ACR70 responses up to 39%, and maintains safety profile after 24 weeks of treatment in DARWIN 1 Phase 2B study Webcast presentation of the results to be held on 30 July 2015, 16.00 CET/10 AM EDT/7
Read more →LKFTRegulated information 19 June 2015 Galapagos raises 4.4 million through warrant exercises Mechelen, Belgium; 19 June 2015 Galapagos NV (Euronext & NASDAQ: GLPG) announced today a share capital increase arising from warra
Galapagos raises 4.4 million through warrant exercises Mechelen, Belgium; 19 June 2015 Galapagos NV (Euronext & NASDAQ: GLPG) announced today a share capital increase arising from Since its inception in 1999, Galapagos has used warrant plans to incentivize personnel and managem
Read more →LKFTRegulated information 18 June 2015 Galapagos completes recruitment for ORIGIN Phase 2 trial with GLPG1205 in ulcerative colitis patients Mechelen, Belgium; 18 June 2015 Galapagos NV (Euronext & NASDAQ: GLPG) announced to
Galapagos completes recruitment for ORIGIN Phase 2 trial with GLPG1205 in ulcerative colitis patients Mechelen, Belgium; 18 June 2015 Galapagos NV (Euronext & NASDAQ: GLPG) announced today it has completed recruitment for the Phase 2 Proof-of-Concept study in ulcerative colitis
Read more →LKFTRegulated information 15 June 2015 AbbVie and Galapagos present cystic fibrosis corrector and potentiator screening approach at ECFS conference Mechelen, Belgium; 15 June 2015 Galapagos NV (Euronext & NASDAQ: GLPG) annou
AbbVie and Galapagos present cystic fibrosis corrector and potentiator screening approach at ECFS conference Mechelen, Belgium; 15 June 2015 Galapagos NV (Euronext & NASDAQ: GLPG) announced a joint presentation with AbbVie (NYSE: ABBV) at the 38th annual European Cystic Fibrosi
Read more →LKFTRegulated information 10 June 2015 Galapagos DARWIN 1 and 2 studies have completed 24 weeks of treatment Last of 886 enrolled rheumatoid arthritis (RA) patients have completed the 24 week visit Topline results from final
Galapagos DARWIN 1 and 2 studies have completed 24 weeks of treatment Belgium; 10 June 2015 - Galapagos NV (Euronext & NASDAQ: GLPG), a clinical stage biotechnology company focused on developing novel mode of action medicines, announces that the last RA patients in its DARWIN 1
Read more →LKFTRegulated information 26 May 2015 Galapagos receives transparency notifications Mechelen, Belgium; 26 May 2015 Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from the Capital Group Companies,
Galapagos receives transparency notifications Mechelen, Belgium; 26 May 2015 Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from the Capital Group Companies, Inc., Fidelity Management and Research LLC, and Federated Equity Management Company of Penns
Read more →LKFTRegulated information 18 May 2015 Galapagos announces full exercise of underwriters option to purchase additional shares Mechelen, Belgium; 18 May 2015 Galapagos NV (Euronext & NASDAQ: GLPG) announced today that the unde
Galapagos announces full exercise of underwriters option to purchase 18 May 2015 Galapagos NV (Euronext & NASDAQ: GLPG) announced today that the underwriters of its global offering have exercised the greenshoe option in full. The greenshoe option granted to the underwriters was
Read more →Competitive Position
How LKFT ranks across every disease it competes inCompetitive Position is a premium feature
See how LKFT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial